Pharm-Olam performed a phase III study in patients with open-angle glaucoma or ocular hypertension to assess the intraocular pressure-lowering efficacy of two compounds. We provided monitoring for all 456 patients in the study with Pharm-Olam selected sites enrolling 292 out of a target 270 patients. The study originally planned to use 43 sites, however due to fast start-up and high recruitment rates at Pharm-Olam’s sites, only 33 sites were initiated. Top recruiting countries included Hungary (121), Italy (59), and Poland (50). Pharm-Olam provided Regulatory and Ethics Submissions, Monitoring, SAE Reporting, Project Management, Training and local pharmacy arrangements.